Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously
- PMID:25617725
- DOI: 10.1016/j.jconrel.2015.01.022
Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously
Abstract
Liposomes are well-established drug delivery systems with cancer chemotherapy as main focus. To increase the cellular drug delivery, liposomes can be endowed with ligands, e.g. recombinant antibody fragments, which ensure specific cell interaction. Multispecific immunoliposomes can be prepared to improve the liposome to cell interaction by targeting multiple different targets at the same time, for instance by coupling two or more different ligands to the liposomal surface, resulting in a synergistic or additive increase in binding. An alternative approach is the use of bispecific ligands to address at least two different targets. For this purpose we cloned a single-chain diabody fragment (scDb`), a bispecific molecule targeting two antigens, endoglin (CD105) and fibroblast activation protein (FAP), expressed on cells of the tumor microenvironment. As model cell system, a human fibrosarcoma cell line was used expressing endoglin and FAP simultaneously. Monospecific immunoliposomes directed either against endoglin or FAP were compared in vitro for cell binding and cytotoxic activity with bispecific dual-targeted scFv`-IL (bispecific scFv`FAP/CD105-IL) and bispecific single-chain diabody`-IL (scDb`CD105/FAP-IL) targeting endoglin and FAP simultaneously. In the underlying study, bispecific scFv`FAP/CD105-IL interacted stronger with cells expressing FAP and endoglin (both targets simultaneously) compared to the monospecific immunoliposomes. Furthermore, bispecific scDb`-immunoliposomes increased the cell interaction massively and showed enhanced cytotoxicity against target cells using doxorubicin-loaded immunoliposomes. The use of recombinant bispecific ligands as scDb`-molecules facilitates the generation of bispecific immunoliposomes by using the established post-insertion technique, enabling an extension of the ligand specificity spectrum via genetic modification.
Keywords: Endoglin; FAP; Immunoliposomes; Single-chain diabody; Targeting.
Copyright © 2015 Elsevier B.V. All rights reserved.
Similar articles
- In vivo near-infrared fluorescence imaging of FAP-expressing tumors with activatable FAP-targeted, single-chain Fv-immunoliposomes.Rüger R, Tansi FL, Rabenhold M, Steiniger F, Kontermann RE, Fahr A, Hilger I.Rüger R, et al.J Control Release. 2014 Jul 28;186:1-10. doi: 10.1016/j.jconrel.2014.04.050. Epub 2014 May 5.J Control Release. 2014.PMID:24810115
- Immunoliposomes for Targeted Delivery of an Antifibrotic Drug.Schuster L, Seifert O, Vollmer S, Kontermann RE, Schlosshauer B, Hartmann H.Schuster L, et al.Mol Pharm. 2015 Sep 8;12(9):3146-57. doi: 10.1021/acs.molpharmaceut.5b00012. Epub 2015 Jul 28.Mol Pharm. 2015.PMID:26181293
- Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.Hornig N, Kermer V, Frey K, Diebolder P, Kontermann RE, Müller D.Hornig N, et al.J Immunother. 2012 Jun;35(5):418-29. doi: 10.1097/CJI.0b013e3182594387.J Immunother. 2012.PMID:22576347
- The application of the fibroblast activation protein α-targeted immunotherapy strategy.Jiang GM, Xu W, Du J, Zhang KS, Zhang QG, Wang XW, Liu ZG, Liu SQ, Xie WY, Liu HF, Liu JS, Wu BP.Jiang GM, et al.Oncotarget. 2016 May 31;7(22):33472-82. doi: 10.18632/oncotarget.8098.Oncotarget. 2016.PMID:26985769Free PMC article.Review.
- The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment.Cheng WW, Allen TM.Cheng WW, et al.Expert Opin Drug Deliv. 2010 Apr;7(4):461-78. doi: 10.1517/17425240903579963.Expert Opin Drug Deliv. 2010.PMID:20331354Free PMC article.Review.
Cited by
- Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions.Abdeldaim DT, Schindowski K.Abdeldaim DT, et al.Pharmaceutics. 2023 Sep 28;15(10):2402. doi: 10.3390/pharmaceutics15102402.Pharmaceutics. 2023.PMID:37896162Free PMC article.Review.
- Smart Lipid-Based Nanosystems for Therapeutic Immune Induction against Cancers: Perspectives and Outlooks.Fobian SF, Cheng Z, Ten Hagen TLM.Fobian SF, et al.Pharmaceutics. 2021 Dec 23;14(1):26. doi: 10.3390/pharmaceutics14010026.Pharmaceutics. 2021.PMID:35056922Free PMC article.Review.
- Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics.Puré E, Blomberg R.Puré E, et al.Oncogene. 2018 Aug;37(32):4343-4357. doi: 10.1038/s41388-018-0275-3. Epub 2018 May 3.Oncogene. 2018.PMID:29720723Free PMC article.Review.
- Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives.Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, Zhang B, Meng Q, Yu X, Shi S.Mao X, et al.Mol Cancer. 2021 Oct 11;20(1):131. doi: 10.1186/s12943-021-01428-1.Mol Cancer. 2021.PMID:34635121Free PMC article.Review.
- Challenges of Current Anticancer Treatment Approaches with Focus on Liposomal Drug Delivery Systems.Gyanani V, Haley JC, Goswami R.Gyanani V, et al.Pharmaceuticals (Basel). 2021 Aug 24;14(9):835. doi: 10.3390/ph14090835.Pharmaceuticals (Basel). 2021.PMID:34577537Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous